Literature DB >> 6743475

The effect of cimetidine on the relative cardioselectivity of atenolol and metoprolol in asthmatic patients.

M E Ellis, M Hussain, A K Webb, N P Barker, T J Fitzsimons.   

Abstract

The effects of chronic cimetidine therapy on the pharmacodynamic properties of atenolol and metoprolol were assessed in eight asthmatic patients using a placebo-controlled trial. When atenolol and metoprolol were administered at doses which achieved an equivalent degree of beta1-adrenoceptor blockade, metoprolol caused a significantly greater reduction in mean forced expiratory volume in one second (FEV1). This demonstrates the greater cardioselectivity of atenolol. The reductions in mean FEV1 induced by either atenolol or metoprolol were each unaffected by cimetidine. Plasma levels of each of the beta-adrenoceptor blockers were not affected by the addition of cimetidine. The FEV1 in one patient was further reduced when cimetidine was administered with metoprolol, although there was no corresponding change in plasma levels of drug. In this patient there was no such further reduction in FEV1 with atenolol. This study has not provided evidence for a pharmacodynamic interaction between cimetidine and either atenolol or metoprolol, but further studies are indicated.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6743475      PMCID: PMC1463253          DOI: 10.1111/j.1365-2125.1984.tb02429.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  13 in total

1.  Comparative bioavailability and effect studies on metoprolol administered as ordinary and slow-release tablets in single and multiple doses.

Authors:  C G Regårdh; G Johnsson; L Jordö; L Sölvell
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1975

2.  Enhancement of the bioavailability of propranolol and metoprolol by food.

Authors:  A Melander; K Danielson; B Scherstén; E Wåhlin
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

3.  Metabolism of atenolol in man.

Authors:  P R Reeves; J McAinsh; D A McIntosh; M J Winrow
Journal:  Xenobiotica       Date:  1978-05       Impact factor: 1.908

4.  Interaction of cimetidine with metoprolol, propranolol, or atenolol.

Authors:  W Kirch; H Köhler; H Spahn; E Mutschler
Journal:  Lancet       Date:  1981-09-05       Impact factor: 79.321

5.  Influence of cimetidine on pharmacokinetics of propranolol.

Authors:  A M Heagerty; M A Donovan; C M Castleden; J F Pohl; L Patel; A Hedges
Journal:  Br Med J (Clin Res Ed)       Date:  1981-06-13

Review 6.  Clinical pharmacokinetics of metoprolol.

Authors:  C G Regårdh; G Johnsson
Journal:  Clin Pharmacokinet       Date:  1980 Nov-Dec       Impact factor: 6.447

7.  Bioavailability of atenolol formulations.

Authors:  J Mcainsh; W T Simpson; B F Holmes; J Young; S H Ellis
Journal:  Biopharm Drug Dispos       Date:  1980 Oct-Dec       Impact factor: 1.627

8.  The gas chromatographic determination of atenolol in biological samples.

Authors:  B Scales; P B Copsey
Journal:  J Pharm Pharmacol       Date:  1975-06       Impact factor: 3.765

9.  Effects on exercise tachycardia during forty-eight hours of a series of doses of atenolol, sotalol, and metoprolol.

Authors:  D W Harron; K Balnave; C D Kinney; R Wilson; C J Russell; R G Shanks
Journal:  Clin Pharmacol Ther       Date:  1981-03       Impact factor: 6.875

10.  Reduction of liver blood flow and propranolol metabolism by cimetidine.

Authors:  J Feely; G R Wilkinson; A J Wood
Journal:  N Engl J Med       Date:  1981-03-19       Impact factor: 91.245

View more
  3 in total

Review 1.  Clinical relevance of cimetidine drug interactions.

Authors:  A F Shinn
Journal:  Drug Saf       Date:  1992 Jul-Aug       Impact factor: 5.606

Review 2.  beta-blockers. Drug interactions of clinical significance.

Authors:  I Blaufarb; T M Pfeifer; W H Frishman
Journal:  Drug Saf       Date:  1995-12       Impact factor: 5.606

Review 3.  Selection of drugs to treat gastro-oesophageal reflux disease: the role of drug interactions.

Authors:  D A Flockhart; Z Desta; S K Mahal
Journal:  Clin Pharmacokinet       Date:  2000-10       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.